Press releases

Beactica nominated as “Technology Rising Star” by Deloitte

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as "Technology Rising Stars” by management consultants Deloitte. "We are delighted to be one of the 25 fastest growing new technology companies in Sweden” says... [...]

Beactica announces fragment-based drug discovery agreement

Uppsala, Sweden, April 27th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery... [...]

Beactica awarded €0.7 million from EU for pioneering influenza research

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza. In the FluCure project, Beactica will apply its proprietary fragment-based... [...]

Beactica announces the appointment of a new Chairman and a new Member to its Board

Uppsala, Sweden, December 14th, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced that board member Gisela Sitbon will assume the position of Chairman and that Mr Jan Mellberg will join its Board, both effective immediately. Dr Gisela Sitbon has more than 25 years experience... [...]

Beactica appoints Dr Evert Homan as Chief Operating Officer

Uppsala, Sweden, September 3rd, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the promotion of Dr Evert Homan to Chief Operating Officer. Evert has been with the Company since 2008 when he joined from Biovitrum. He has more than ten years experience from the international... [...]

Beactica awarded grant for pioneering brain research

Uppsala, Sweden, August 9th, 2010 Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a European expertise network that will address human brain disease. The network, called SynSys, has been awarded funding through the 7th EU Framework Programme and aims to achieve... [...]

Dr Gisela Sitbon joins the Board of Beactica

Uppsala, Sweden, February 3rd, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Dr Gisela Sitbon to its Board. Dr Sitbon, Deputy Region Director at Innovationsbron AB, brings more than 25 years experience from the life science industry within the areas... [...]